Drug Discovery

Moderna and Lonza announce worldwide strategic collaboration to manufacture Moderna’s vaccine against novel coronavirus

Moderna, a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and Lonza announced a 10-year strategic collaboration agreement to enable larger scale manufacture of Moderna’s mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2) and additional Moderna products in the future.

Default Table Multi-Parameter Transmitter M800

The M800 multi-parameter transmitter provides simultaneous monitoring of one, two or four in-line sensors. It offers measurement of pH/ORP, optical DO, amperometric oxygen (DO as well as O2 gas), conductivity, resistivity, TOC, dissolved ozone, flow and turbidity in pure water as well as process applications.

Quotient Sciences and CytoAgents accelerate potential treatment for COVID-19 cytokine storm

A collaboration to accelerate the development of a lead COVID-19 drug candidate into human clinical trials was announced today by Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, and CytoAgents, Inc., a privately held biotechnology company focused on the development of pharmaceutical products for the treatment of viral infectious diseases.

Merck and Institute for Systems Biology collaborate to define molecular mechanisms of SARS-CoV-2 infection and identify potential prognostic biomarkers

Merck, known as MSD outside the United States and Canada, and the Institute for Systems Biology (ISB), announced a new research collaboration to investigate and define the molecular mechanisms of SARS-CoV-2 infection and COVID-19 and identify targets for medicines and vaccines.

Affinia secures $1.6bn worth deal from Vertex to develop AAV capsids for genetic therapies

Affinia Therapeutics has signed a research collaboration deal worth more than $1.6bn with Vertex Pharmaceuticals to discover and develop adeno-associated virus capsids (AAV capsids) to be used in the latter's genetic therapies aimed at treating people with serious diseases.

Affinivax announces $120m Series B financing to advance pipeline of novel MAPS vaccines and immunotherapies

Affinivax, a clinical stage biotechnology company with its novel MAPS technology platform for vaccines and immunotherapies, today announced the completion of a $120 million Series B financing round, led by Viking Global Investors with participation from Bain Capital Life Sciences and Ziff Capital Partners.

Agastiya Biotech proceeding with drug candidate for COVID-19

Agastiya Biotech announces it has discovered its previously tested anti-cancer small molecule AB001 as a viable SARS-CoV-2 virus therapeutic.

Gilead, oNKo-innate to develop NK cells-focused cancer immunotherapies

Gilead Sciences and its subsidiary Kite have joined forces with oNKo-innate to discover and develop cancer immunotherapies focused on natural killer (NK) cells.

Revive Therapeutics partners with Complete Phytochemical Solutions to advance research initiatives for psilocybin-based pharmaceutical products

Revive Therapeutics has engaged Complete Phytochemical Solutions, which specialises in unique and complex analyses and formulation development of phytochemicals, to advance the Company’s research and development initiatives of psilocybin-based products for the pharmaceutical market.